ENT Department, City Hospitals Sunderland NHS Foundation Trust, Sunderland, UK.
ENT Department, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
J Laryngol Otol. 2020 Dec;134(12):1103-1107. doi: 10.1017/S0022215120002704.
Wide-ranging outcomes have been reported for surgical and non-surgical management of T3 laryngeal carcinomas. This study compared the outcomes of T3 tumours treated with laryngectomy or (chemo)radiotherapy in the northeast of England.
The outcomes of T3 laryngeal carcinoma treatment at three centres (2007-2016) were retrospectively analysed using descriptive statistics and survival curves.
Of 179 T3 laryngeal carcinomas, 68 were treated with laryngectomies, 57 with chemoradiotherapy and 32 with radiotherapy. There was no significant five-year survival difference between treatment with laryngectomy (34.1 per cent) and chemoradiotherapy (48.6 per cent) (p = 0.184). The five-year overall survival rate for radiotherapy (12.5 per cent) was significantly inferior compared to laryngectomy and chemoradiotherapy (p = 0.003 and p < 0.001, respectively). The recurrence rates were 22.1 per cent for laryngectomy, 17.5 per cent for chemoradiotherapy and 50 per cent for radiotherapy. There were significant differences in recurrence rates when laryngectomy (p = 0.005) and chemoradiotherapy (p = 0.001) were compared to radiotherapy.
Laryngectomy and chemoradiotherapy had significantly higher five-year overall survival and lower recurrence rates compared with radiotherapy alone. Laryngectomy should be considered in patients unsuitable for chemotherapy, as it may convey a significant survival advantage over radiotherapy alone.
手术和非手术治疗 T3 喉癌的结果差异较大。本研究比较了英国东北部采用喉切除术或(放)化疗治疗 T3 肿瘤的结果。
使用描述性统计和生存曲线对三个中心(2007-2016 年)的 T3 喉癌治疗结果进行回顾性分析。
179 例 T3 喉癌中,68 例行喉切除术,57 例行放化疗,32 例行放疗。喉切除术(34.1%)与放化疗(48.6%)的五年生存率无显著差异(p=0.184)。放疗(12.5%)的五年总生存率明显低于喉切除术和放化疗(p=0.003 和 p<0.001)。喉切除术的复发率为 22.1%,放化疗为 17.5%,放疗为 50%。与放疗相比,喉切除术(p=0.005)和放化疗(p=0.001)的复发率存在显著差异。
与单纯放疗相比,喉切除术和放化疗具有更高的五年总生存率和更低的复发率。对于不适合化疗的患者,应考虑行喉切除术,因为与单纯放疗相比,它可能具有显著的生存优势。